Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders

NEUROFGL

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and...

Funding Programme
Start Date
End Date
Total Funding
€ 7 807 910
European Countries Involved

Establishing Target Engagement and Selectivity for CTP Inhibitors in Cells: Synthesis and Application of CHOLesterol Probes for a Comprehensive MAPping of the Cholesterol Interactome

CholMap

Cholesterol is a structural component of membranes and plays a key role in human health by regulating the fluidity of membranes and affecting signaling pathways. Intracellular cholesterol transport proteins (CTP) are responsible for maintaining cholesterol homeostasis by regulating local cholesterol concentrations, arising from de novo biosynthesis...

Funding Programme
Start Date
End Date
Total Funding
€ 247 553
European Countries Involved

European Bank for induced pluripotent Stem Cells

EBiSC

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...

Funding Programme
Start Date
End Date
Total Funding
€ 34 327 858
European Countries Involved

European Medical Information Framework

EMIF

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information...

Funding Programme
Start Date
End Date
Total Funding
€ 53 642 677

European Prevention of Alzheimer’s Dementia Consortium

EPAD

The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions.

To achieve this, EPAD...

Funding Programme
Start Date
End Date
Total Funding
€ 53 237 842

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EURIPIDES

'We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against...

Funding Programme
Start Date
End Date
Total Funding
€ 9 086 523
European Countries Involved

Focused ultrasound and microbubbles targeting alpha-synuclein pathology-related dementia (FUMA)

FUMA

Over half of Parkinson Disease patients develop cortical dysfunctions leading to Parkinson Disease Dementia (PDD). The cognitive changes are primarily driven by pathological alpha-synuclein (a-syn) protein aggregates with secondary synaptic dysfunctions in the cortex. Microglia plays a key role in synapse maintenance and clearance of aggregated a...

Funding Programme
Start Date
End Date
Total Funding
€ 230 774
European Countries Involved

FROM PATIENT DATA TO PERSONALISED HEALTHCARE IN ALZHEIMER'S DISEASE

PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades. Alzheimer's disease (AD) covers 60-70% of all dementia cases. No...

Funding Programme
Start Date
End Date
Total Funding
€ 3 908 233
European Countries Involved

Generalised EMF Research using Novel Methods – an integrated approach: from research to risk assessment and support to risk management

GERONIMO

The EU population is increasingly exposed to new physical and chemical agents in the environment, some of which may be detrimental to public health. Of these, electromagnetic fields (EMF) are one of the most ubiquitous, with new EMF technologies and novel applications being actively developed and commercialised. To address pertinent questions on...

Funding Programme
Start Date
End Date
Total Funding
€ 7 853 407

Genomic Instability in Alzheimer’s Disease and Related Disorders: a Single-Cell Approach

INSTALZ

Increasing evidence suggests that the genetic information in our bodies can vary from cell to cell. Such variation has also been found in the brain, although its consequences for brain function or disease remain largely unknown. In this project, we will study the role of genomic instability in Alzheimer's disease and related tauopathies. The...

Funding Programme
Start Date
End Date
Total Funding
€ 1 837 608
European Countries Involved

Hijacking small hydrophobic protein transport to deliver therapeutic agents to the central nervous system

SH-CNS-AM

Neurological disorders affect over 540 million individuals in Europe alone, yet effective treatments are limited, primarily due to the challenge of delivering therapeutic compounds across the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). This project aims to develop a novel, virus-inspired technology that utilizes...

Funding Programme
Start Date
End Date
Total Funding
€ 263 393
European Countries Involved

Identification of personalized inflammatory profiles of aging and senescence which are modified specifically by risk factors of dementia modulating the predementia speed of symptomatic progression.

PREADAPT

Age represents by far the largest risk factor for dementia, including Alzheimer’s disease (AD) dementia. However, not every person will develop dementia during aging, indicating that age-related processes may not inescapably lead to dementia. The elucidation of the fundamental processes occurring in aging will likely offer new options to prevent or...

Funding Programme
Start Date
End Date
Total Funding
€ 2 400 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).